Mabgeek Therapeutics

Mabgeek Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation antibody-drug conjugates (ADCs) for oncology. The company utilizes a proprietary site-specific conjugation platform that leverages glycan engineering to produce highly homogenous and stable therapeutic candidates. Its lead program, MGK001, is an ADC targeting Claudin 18.2, which has received IND clearance for clinical evaluation in patients with advanced solid tumors. Beyond its lead asset, Mabgeek is advancing a pipeline of ADCs and multi-specific antibodies targeting well-validated and novel tumor antigens. Headquartered in Shanghai, China, the firm is supported by prominent venture capital investors and led by a management team with deep expertise in antibody discovery.